

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>		
				Application Number	Not Yet Assigned	
Sheet		1	of	3	Attorney Docket Number	PZ029P1D3
					Examiner Name	Not Yet Assigned
					Group Art Unit	N/A
					First Named Inventor	Ruben et al.
					Filing Date	Concurrently Herewith

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
/FH/	AA	5,534,409		Groner et al.	07/09/1996	
/FH/	AB	5,250,414		Schwab et al.	10/05/1993	
/FH/	AC	5,684,133		Schwab et al.	11/04/1997	
/FH/	AD	6,103,232		Schwab et al.	08/15/2000	
/FH/	AE	5,011,912		Hopp et al.	04/30/1991	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
/FH/	AF	WO	99/66041		Human Genome Sciences, Inc.	12/23/1999	
	AG	WO	01/51520	A2	Yale University	07/19/2001	
	AH	WO	99/46281	A2	Genentech, Inc.	09/16/1999	
	AJ	WO	00/32221	A2	Genentech, Inc.	06/08/2000	
	AJ	WO	00/37638	A2	Genentech, Inc.	06/29/2000	
	AK	WO	00/53758	A2	Genentech, Inc.	09/14/2000	
	AL	WO	00/53756	A2	Genentech, Inc.	09/14/2000	
	AM	WO	00/70050	A1	Genentech, Inc.	11/23/2000	
	AN	WO	00/73452	A2	Genentech, Inc.	12/07/2000	
	AO	WO	01/40466	A2	Genentech, Inc.	06/07/2001	

Examiner Signature	/Fozia Hamud/	Date Considered	07/21/2007
--------------------	---------------	-----------------	------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Concurrently Herewith
		First Named Inventor	Ruben et al.
		Group Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet 2 of 3	Attorney Docket Number	PZ029P1D3	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
/FH/	AP	Geneseq Accession No. AAY86244, "Human secreted protein HCEJQ69, SEQ ID NO:159." (12/23/1999)	
/FH/	AQ	Geneseq Accession No. AAY41745, "Human PRO526 protein sequence." (09/16/1999)	
/FH/	AR	Geneseq Accession No. AAB44301, "Human PRO526 (UNQ330) protein sequence SEQ ID NO:400." (09/14/2000)	
/FH/	AS	Geneseq Accession No. AAB33426, "Human PRO526 protein UNQ330 SEQ ID NO:62." (09/14/2000)	
/FH/	AT	Geneseq Accession No. AAB24410, "Human PRO526 protein sequence SEQ ID NO:127." (06/08/2000)	
/FH/	AU	Geneseq Accession No. AAY95345, "Human PRO526 antitumour protein." (06/29/2000)	
/FH/	AV	Geneseq Accession No. AAB50908, "Human PRO526 protein." (12/07/2000)	
/FH/	AW	Geneseq Accession No. AAB49891, "Human PRO526 protein sequence." (11/23/2000)	
/FH/	AX	Genbank Accession No. AAG53612, "Nogo receptor [Homo sapiens]." (01/24/2001)	
/FH/	AY	Genbank Accession No. AAG53611, "Nogo receptor [Mus musculus]." (01/24/2001)	
/FH/	AZ	Genbank Accession No. AX047642, "Sequence 1 from Patent WO0070050." (12/15/2000)	
/FH/	BA	Genbank Accession No. AA452195, "zx30d02.r1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:787971 5' similar to SW:ALS_HUMAN P35858 insulin-like growth factor binding protein complex acid labile chain precursor, mRNA sequence." (06/05/1997)	
/FH/	BB	Genbank Accession No. AA436362, "zv32e09.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755368 3', mRNA sequence." (05/30/1997)	
/FH/	BC	Genbank Accession No. H08678, "yi93d10.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:46062 3', mRNA sequence." (06/23/1995)	
/FH/	BD	Genbank Accession No. AA428418, "zw32d07.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:770989 5', mRNA sequence." (10/16/1997)	
/FH/	BE	Genbank Accession No. AA427404, "zw32d07.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:770989 3', mRNA sequence." (10/16/1997)	
/FH/	BF	Genbank Accession No. AA410412, "zv32g09.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755392 5', mRNA sequence." (05/18/1997)	
/FH/	BG	Genbank Accession No. AA410413, "zv32g09.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755392 3', mRNA sequence." (05/18/1997)	
/FH/	BH	Genbank Accession No. H08677, "yi93d10.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:46062 5' similar to SP:CBP8_HUMAN P22792 carboxypeptidase N 83 KD chain, mRNA sequence." (06/23/1995)	

Examiner Signature	/Fozia Hamud/	Date Considered	07/21/2007
--------------------	---------------	-----------------	------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Ruben et al.
				Group Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	PZ029P1D3

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/FH/	BI	FOURNIER ET AL., "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration", Nature, 409(6818):341-346 (2001)			
/FH/	BJ	GRANDPRE et al., "Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein", Nature, 403(6768):439-444 (2000)			
/FH/	BK	GOLDBERG ET AL., "Nogo in nerve regeneration", Nature, 403(6768):369-370 (2000)			
/FH/	BL	JACOBS ET AL., "A genetic selection for isolating cDNAs encoding secreted proteins", Gene, 198:289-296 (1997)			
/FH/	BM	BRITTIS, ET AL., "Nogo Domains and a Nogo Receptor: Implications for Axon Regeneration," Neuron 30:11-14 (2001).			
/FH/	BN	Ng, C.E. and B.L. Tang., "Nogos and the Nogo-66 Receptor: Factors inhibiting CNS neuron regeneration," J. Neurosci Res 67(5):559-565 (2002).			
/FH/	BO	GrandPrè, T., et al., "Nogo-66 Receptor Antagonist Peptide Promotes Axonal Regeneration," Nature Vol 417 (30 May 2002)			

Examiner Signature	/Fozia Hamud/	Date Considered	07/21/2007
--------------------	---------------	-----------------	------------

² Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.